AUtomated Risk Assessment for Stroke in Atrial Fibrillation (AURAS-AF) - an automated software system to promote anticoagulation and reduce stroke risk: study protocol for a cluster randomised controlled trial by Tim A Holt et al.
TRIALS
Holt et al. Trials 2013, 14:385
http://www.trialsjournal.com/content/14/1/385STUDY PROTOCOL Open AccessAUtomated Risk Assessment for Stroke in Atrial
Fibrillation (AURAS-AF) - an automated software
system to promote anticoagulation and reduce
stroke risk: study protocol for a cluster
randomised controlled trial
Tim A Holt1*, David A Fitzmaurice2, Tom Marshall3, Matthew Fay4, Nadeem Qureshi5, Andrew R H Dalton1,
F D Richard Hobbs1, Daniel S Lasserson1, Karen Kearley1, Jenny Hislop1 and Jing Jin1Abstract
Background: Patients with atrial fibrillation (AF) are at significantly increased risk of stroke. Oral anticoagulants
(OACs) substantially reduce this risk, with gains seen across the spectrum of baseline risk. Despite the benefit to
patients, OAC prescribing remains suboptimal in the United Kingdom (UK). We will investigate whether an
automated software system, operating within primary care electronic medical records, can improve the
management of AF by identifying patients eligible for OAC therapy and increasing uptake of this treatment.
Methods/Design: We will conduct a cluster randomised controlled trial, involving general practices using the
Egton Medical Information Systems (EMIS) Web clinical system. We will randomise practices to use an electronic
software tool or to continue with usual care. The tool will a) produce (and continually refresh) a list of patients with
AF who are eligible for OAC therapy - practices will invite these patients to discuss therapy at the start of the trial -
and b) generate electronic screen reminders in the medical records of those eligible, appearing throughout the trial.
The software will run for 6 months in 23 intervention practices. A total of 23 control practices will manage their AF
register in line with the usual care offered. The primary outcome is change in proportion of eligible patients with
AF who have been prescribed OAC therapy after six months. Secondary outcomes are incidence of stroke, transient
ischaemic attack, other major thromboembolism, major haemorrhage and reports of inappropriate OAC prescribing
in the data collection sample - those deemed eligible for OACs. We will conduct a process evaluation in parallel
with the randomised trial. We will use qualitative methods to examine patient and practitioner views of the inter-
vention and its impact on primary care practice, including its time implications.
Discussion: AURAS-AF will investigate whether a simple intervention, using electronic primary care records, can
improve OAC uptake in a high risk group for stroke. Given previous concerns about safety, especially surrounding
inappropriate prescribing, we will also examine whether electronic reminders safely impact care in this clinical area.
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Despite improving trends in incidence, stroke remains a
major health burden in the United Kingdom (UK), and
internationally. Cerebrovascular disease is still the sec-
ond largest cause of mortality in England and Wales [1],
and has a greater disabling impact than any other
chronic disease [2]. Improved management of risk fac-
tors has been central to recent improvements in out-
comes [3], but a notable exception is the management of
stroke risk in patients with atrial fibrillation (AF).
AF is a major independent risk factor for stoke, con-
veying up to a five-fold increased risk [4]. AF-associated
strokes are generally more severe, with greater case fatal-
ity and subsequent disability than those not associated
with AF [5]. Anticoagulation is established as an effect-
ive method of reducing stroke risk (by up to 67%) in pa-
tients with AF [6,7]. Despite the evidence of benefit,
however, there remains considerable underuse. Recent
studies place UK prescribing at as low as 53 percent of
those eligible (based on national clinical guidelines of
the time) [8], with up to 34 percent not prescribed and
without a recorded contraindication or refusal [9]. This
underuse is also evident internationally [10,11]. A num-
ber of factors contribute to this, including clinician mis-
conceptions over risk of haemorrhage, especially in older
people; time implications of the management of the
most commonly used anticoagulant, warfarin; and con-
fusion over eligibility [12]. There are risks from anticoa-
gulation, notably haemorrhage, and some patients at
high risk of bleeding should be excluded from this treat-
ment. The pros and cons of anticoagulation are, how-
ever, often misjudged by clinicians, and based on the
balance between haemorrhage and thromboembolism
risk, most should be considered for OACs [13].
Decision support tools have been highlighted as one
option to promote evidence-based prescribing of antico-
agulants in AF [14]. Patient-specific electronically gener-
ated reminders - those which draw on routine medical
record data to generate reminders specific to a patient -
produce moderate, but significant, improvements in
clinical processes, including prescribing [15]. However,
concerns remain over their use, including the appropri-
ateness of discussing issues outside the patient’s agenda
during a consultation (resulting in a loss of patient au-
tonomy) [16]; their impact on consultation length and
flow [17]; and clinicians developing a reliance on them
[18]. In the case of OAC therapy in AF, there is an added
risk that an important decision might be rushed in the
opportunistic setting.
We aim to develop an intervention to promote oral
anticoagulation in eligible patients with AF (defined by
the National Institute for Health and Clinical Excellence
(NICE) guidance TA249 [19]), and further to test its ef-
fectiveness and safety. We do not differentiate betweentypes of OAC (for example the most commonly used
warfarin, or newer OACs such as dabigatran). Our inter-
vention builds on the approach of the existing GRASP-
AF tool [9] (drawing on routinely collected primary care
data to identify eligible individuals with AF for OAC),
but in addition will automatically update itself by repeat-
edly interrogating the practice database, and will be
linked to screen reminders. Our intervention follows the
established principle of repeated, electronically embedded
audit cycles in primary care, typified by the UK Quality
and Outcomes Framework (QOF) that supports the care
of the more common chronic diseases [20]. Critically, to
our knowledge, no such tool has been previously assessed
in a randomised trial in this area of care.
Aim
The aim of this trial is to investigate the impact of an auto-
mated system to identify patients with AF who are eligible
for oral anticoagulant therapy (defined by NICE guidance
TA249 [19]) to reduce stroke risk and to identify barriers
to commencing recommended care using the tool.
Objectives
The objectives of this trial are as follows:
1. To examine whether an automated software system
operating within electronic medical records to
identify patients with AF who are eligible for oral
anticoagulant therapy will increase uptake.
2. To investigate whether the electronic software
system can produce short term reductions in
thromboembolism in high risk patients with AF.
3. To examine the safety of the electronic software
system in promoting anticoagulation in patients with
AF, including its impact on inappropriate prescribing
and haemorrhages.
4. To examine patient and practitioner views of
electronic systems that incorporate automated
reminders in primary care and their impact on the
primary care consultation and practice.
5. To investigate barriers and enablers to the successful
uptake of an electronic audit and reminder tool to
promote anticoagulation in patients with AF by
primary care teams.
6. To explore reasons why patients with AF are not
prescribed anticoagulants and identify any barriers
to recommended prescribing that persist after the
use of an electronic audit and reminder system.
Methods/Design
Study design
We will use a cluster randomised controlled trial (Figure 1)
to investigate whether a decision support tool in electronic
primary care records safely increases anticoagulant
Figure 1 Outline design of the AURAS-AF trial. AF = Atrial Fibrillation; GP = General Practitioner.
Holt et al. Trials 2013, 14:385 Page 3 of 9
http://www.trialsjournal.com/content/14/1/385prescribing in eligible patients with AF. The general prac-
tice is the unit of allocation and study participant because
the intervention aims to improve prescribing at a practice
level. The intervention phase will last for 6 months, with
data collection immediately following, and after a further
6 months. Control practices will undergo pre-/post-assess-
ment, but will not receive the active software tool. We
shall conduct a 3-month pilot study before the main
phase, and a process evaluation in parallel with it.
Study setting and population
The study is set in English general practices, situated
within the South East of England, Central England, and
East Midland and South Yorkshire Primary Care Re-
search Networks (PCRNs), which use the EMIS Web
clinical system. We exclude practices that have carried
out a major audit of anticoagulant prescribing (including
the systematic invitation of patients) within the last
2 years; those previously involved in research into antic-
oagulation (including those involved in the pilot study)
or those who have begun using the EMIS Web system
within the last 3 months. EMIS are the largest among
several providers of clinical software to UK general prac-
tice and their Web version is becoming widely adopted
across the UK. Study practices will be recruited through
a letter of invitation sent from the study team, through
the local PCRN, with a practice guardian providingconsent [21,22]. All practices using EMIS Web within
the study region will be given equal opportunity to par-
ticipate in the study.
Intervention
The intervention is an electronic software tool installed
in practice clinical systems. The tool identifies patients
with AF who are eligible for anticoagulants based on re-
cent guidelines (NICE TA249) [19], and are not cur-
rently prescribed therapy. We have designed the tool to
operate in the EMIS Web clinical system. The tool will
identify eligibility by interrogating data held in patient
medical records. The NICE TA249 eligibility criteria are
operationalised using the relevant clinical codes (see
Additional file 1). Given that some criteria defining eligi-
bility (see below) may be poorly coded, the tool high-
lights (through screen messages) patients with suspected
relevant diagnoses (diabetes, heart failure, or hyperten-
sion), based on other aspects of their medical record
(detailed decision rules available from the authors).
These must be addressed by the clinician, with the diag-
nosis either confirmed or rejected, before proceeding.
For instance, in current practice, most patients with
known, symptomatic heart failure will be on the QOF
Heart Failure register, a register that requires echocar-
diographic evidence of reduced left ventricular ejection
fraction or a diagnosis of heart failure by a cardiologist.
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they have neither NYHA class 2 symptoms (or greater)
nor echocardiographic evidence of a low ejection frac-
tion. However, in cases not on the register but where
clinical codes suggest they should be, this will be ques-
tioned using automatically generated screen messages.
Similar decision rules apply to possible uncoded diabetes
and hypertension. In addition, the tool requests clarifica-
tion over the nature (thromboembolic or haemorrhagic)
of past recorded strokes, where non-specific electronic
codes have been applied to the record. This is important
as the distinction has a very important influence on eli-
gibility for OAC therapy. This clarification is obtained
by responses to screen prompts and these responses will
be collected during the study.
The tool has two components:
1. A search module that maintains a list of patients
diagnosed with AF, highlighting the group eligible
for anticoagulation under current recommendations
and who are currently not prescribed OAC therapy.
According to NICE TA249 [19] patients are
considered eligible if they meet one or more of the
following criteria:
 previous stroke, transient ischaemic attack or
systemic embolism
 left ventricular ejection fraction below 40%
 symptomatic heart failure of New York Heart
Association (NYHA) class 2 or above
 age 75 years or older
 age 65 years or older with one of the following:
diabetes mellitus, coronary artery disease or
hypertension.Once activated, the software will automatically refresh
the list every 24 hours using data in the electronic med-
ical records.
2. It will generate onscreen reminders, prompting
clinicians (either general practitioners or practice
nurses) about the need for anticoagulation in
patients with AF. Screen reminder messages will
appear whenever the electronic record of a patient
eligible for, but not currently being prescribed
anticoagulants, is opened by a clinician. These
reminders must be actively responded to, with the
clinician choosing from a number of options as
indicated below. Options 1 and 2 will remove the
screen message, but it will return next time the
record is opened; options 3 and 4 will remove the
screen message, which will not reappear as long as
the corresponding ‘Read’ code is entered into the
record or an OAC is prescribed respectively; option
5 permanently stops reminders.The wording of the reminder is as follows:
This patient with Atrial Fibrillation is at raised risk of
stroke. Anticoagulation is recommended unless con-
traindicated.
Please indicate your intended management:
1. I am not a clinician able to initiate anticoagulant
therapy.
2. We do not have time to decide during this
consultation over starting anticoagulation.
3. The patient is already taking anticoagulation,
so no action needed, but I will apply the code
‘Anticoagulation monitoring’ to stop further alerts
appearing.
4. We intend to start anticoagulation.
5. We have decided not to start anticoagulation
because (tick all that apply):
* Evidence of atrial fibrillation (or history of it) is
absent/inconclusive
* Patient preference (after benefits have been
explained & risks discussed)
* Concern over on-going risk of serious
haemorrhage
* Other reason/s (which I am recording in the
notes)Note - changes may be made to wording before the
main phase, dependent on pilot results.
Intervention implementation
The intervention will be delivered into practices
remotely over the EMIS Web system, and then acti-
vated on day 1 of the trial. Participant practices will
receive information about the intervention from the
study team prior to the study. This is a pragmatic trial,
in which we will test the electronic intervention in rou-
tine practice. Intervention practices will agree to invite
all patients on the list produced by the tool at the start
of the trial, excluding those clearly unsuitable, for a
consultation to discuss OAC therapy. The invitations
will include an information sheet, provided by the study
team, which gives patients details about AF and anti-
coagulation. Invitations will be sent within the first
week of the trial, with reminders to non-attendees after
one month.
Additionally, from day 1 of the trial screen reminders
will appear in the medical records of eligible patients.
Both the lists and screen reminders aim simply to pro-
mote current UK guidelines, and not novel management
of AF [19].
Control practices
Control practices will continue with usual care, which as
of April 2012 included requirements placed on practices
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The control practices will have the trial software in-
stalled, but this will run in a non-active format. There
will be no eligible list generated and no screen re-
minders. The software will record the number of pa-
tients eligible for anticoagulation, the number receiving
treatment and other secondary study outcomes through-
out the trial.Study outcomes
Primary outcome
The primary outcome will be the proportion of patients
with diagnosed AF, and eligible for anticoagulation
under recent guidelines (NICE TA249) [19], who are
prescribed therapy 6 months after the start of the
intervention.Secondary outcomes
Secondary outcomes include the following:
1. The proportion of patients with CHADS2 score ≥2
prescribed anticoagulants. CHADS2 is a commonly
used scoring system for stroke risk in atrial
fibrillation [8].
2. A record of inappropriate care or prescribing related
to anticoagulation in patients with AF.
3. The incidence of stroke, transient ischaemic attack
(TIA), or other major thromboembolism during the
trial, in patients with AF eligible for OAC.
4. The incidence of major haemorrhage during the trial
in patients with AF eligible for OAC.
The denominator for the primary outcome will be all
of those eligible for OAC therapy at the end of the
6-month trial period. This will include those whose eligi-
bility has arisen since the start of the trial, for instance
through reaching the 65- or 75-year age thresholds, or
through a new diagnosis of a condition relevant to eligi-
bility. It is important that the size of the denominator
population is not influenced by use of the tool, as this
could lead to ascertainment bias. We will therefore ex-
clude from the outcome denominator those whose eligi-
bility has arisen during the study purely as a result of
improved recognition of diabetes, hypertension, heart
failure, or thromboembolic stroke by the AURAS-AF
tool, as the control arm will not be influenced by this
improved recognition (see ‘Intervention’ section above).
This group will be identifiable through the recording of
responses to screen prompts. Patients diagnosed with
these conditions independently of the tool will not be
excluded. Similarly, cases where an ‘Atrial Fibrillation
Resolved’ code is applied (effectively removing the pa-
tient from the study population) will be retained in thedenominator if this decision resulted directly from the
use of the AURAS-AF tool in the intervention arm.
Allocation
The 46 EMIS Web practices that consent to participate
will be randomised into two equal groups (intervention
and control). We will use balanced allocation due to the
small number of practices. An independent statistician
will randomise practices using block randomisation,
stratifying for practice list size and the proportion of
their eligible population prescribed OACs (groups sepa-
rated by the median).
Data collection
The primary data collection will use the capabilities of
EMIS Web. The research team will enter into data shar-
ing agreements with practices allowing us to securely ac-
cess anonymous outcome data over an N3 NHS (secure)
internet connection. Proportions of patients prescribed
OACs, and incidence of stroke, TIA, other major
thromboembolism and major haemorrhage in the TA249
eligible sample will be collected in this way. We will col-
lect these outcomes at baseline, 3 months into the trial
(for the data monitoring committee), at 6 months (at the
end of the intervention phase) and after 12 months (see
Additional file 1).
We shall additionally ask practices - both intervention
and control - to fill in pro forma providing further infor-
mation on strokes, TIAs, other major thromboembo-
lisms and major haemorrhages. The number of these
required from each individual practice is expected to be
small. These will include information about the anticoa-
gulation status (including international normalised ratio
if available) at the time of the event and duration on
therapy. The pro forma data will help to attribute out-
come events to decisions around prescribing and the
possible influence of the AURAS-AF software on these
decisions. Intervention practices will also be asked to
complete pro forma providing details of patients’ contact
with the practice during the study that is relevant to
anticoagulation. This will include responses to the initial
invitation to consultation, and reasons behind decisions
over therapy where discussions occurred. The main out-
come data will be extracted immediately following the
intervention phase, including the pro forma, with a sec-
ond extract after a further 6 months. Finally, we ask
practices to report any inappropriate care or prescribing
in the AF population to the study team within one week
of its occurrence.
Statistical analyses
We will compare baseline characteristics of randomised
practices and their demographic characteristics between
trial arms. For all randomised practices, we will report
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the start of the study, the proportion of these invited
(with reasons if not invited), the proportion of attendees,
and the proportion of those attending that commence
anticoagulation by the end of the trial.
The anonymous data on anticoagulant prescribing
from each practice will be aggregated and analysed
using analysis of covariance (ANCOVA). We shall
compare proportions of eligible patients who are
using anticoagulation after 6 months, between inter-
vention and control arms (primary outcome), adjust-
ing for baseline values. We shall also compare this
measure using data from one year after the start of
the study. We will assess whether any practice char-
acteristics have an impact on the intervention effect
using multivariable regression. Incidence rates of
stroke, TIA, other major thromboembolisms and
major haemorrhage (secondary outcomes) will be
compared between arms [23].
Pilot study
A 3-month pilot study will be conducted before the
main phase of the trial. The pilot is designed to assess
limitations in the usability and appropriateness of the
intervention and trial material. Main outcomes will be
improvements to the electronic tool and trial material
before the main phase of the study.
We will install the intervention tool into three pilot
practices. These practices will take on the study proce-
dures: briefly, having the list of those eligible produced,
inviting patients to consultation, reminding non-at-
tendees after one month, and having the screen re-
minders activated. We shall interview two patients and
two staff (one general practitioner (GP) and one other
member) per practice. These interviews will focus on the
usability and appropriateness of the electronic tool and
patient material. Finally, we will remotely extract out-
come data approximately one month into the pilot to
test the extraction system.
Process evaluation
The process evaluation, running in parallel with the
intervention phase, will produce important study out-
comes. The process evaluation aims:
1. To examine patient and practitioner views of
electronic reminder systems in primary care, and
their impact on consultations and practice.
2. To investigate barriers and enablers to the successful
take up of an electronic audit and reminder tool by
primary care teams.
3. To explore any barriers to recommended prescribing
in AF that persist after the use of an electronic audit
and reminder system.We will collate data on the responses made to the
screen reminders throughout the intervention period (that
is, option chosen in response to a screen message). This
will be logged by the intervention tool, and accessed re-
motely after the intervention phase. These data will allow
us to study the suitability of the reminders.
The core of the process evaluation will be qualitative
work with GPs and patients in intervention practices.
We shall carry out semi-structured interviews with 10
GPs and up to 30 patients (a maximum of 1 and 5 re-
spectively per practice), stopping if data saturation is
reached (see Additional files 2 and 3). Intervention prac-
tices will identify patients and GPs eligible for interview,
namely those who have been in contact with the inter-
vention. We seek GP interview participants with max-
imum variability across practice list size and the location
of the practice.
Interview participants will give individual consent, in
addition to practice consent. GP interviews will focus on
their views about the software tool, concentrating on im-
pacts of the screen reminders on the consultation
process, how well the software promotes best practice
prescribing and any persisting perceived barriers to pre-
scribing. We shall interview patients who have had a
consultation to discuss anticoagulation as a result of the
trial, stratifying by whether attendance resulted from the
invite letter or an opportunistic reminder. We seek pa-
tients views on screen reminders in primary care, for ex-
ample their thoughts on the change of subject of the
consultation that they create [16], and on opportunistic
health promotion - compared to the systematic ap-
proach of the letters. Interview transcripts will be ana-
lysed thematically and entered into a specialist software
package (NVivo 9). We will organise and analyse emer-
gent themes using the method of constant comparison.
Sample size calculation
We have powered the study to detect changes in one of
the secondary outcomes - change in proportion with
CHADS2 score ≥2 who are prescribed anticoagulants.
This is a smaller group than the denominator for the
primary outcome, hence the need for greater power, but
is important given its prominence in the QOF. We esti-
mate a sample of 46 practices will be needed for the
trial, accounting for clustering, variation in cluster size
and 10 percent withdrawals [24]. This will give 95 per-
cent power to detect a relative difference of 25 percent
in proportion of eligible people who are treated between
the trial arms, at 5 percent significance level.
The cluster size (m - number of patients with
CHADS2 ≥2 in each practice) is estimated at 54 (based
on mean list size and AF prevalence in the QOF [25],
and recent CHADS2 estimates [8]). There is no relevant
estimate of minimum change due to intervention;
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on preliminary discussions. We estimated baseline pre-
scribing of 53 percent [8], therefore 66 percent at
follow-up. Assuming an intra-class correlation coeffi-
cient (ICC) of 0.03 (using a published ICC for inappro-
priate prescribing in the elderly [26]) and coefficient of
variation (cv) of cluster size of 0.6 (based on a sample of
THIN data on file; mean AF patients per practice = 119,
standard deviation = 72) we estimate the design effect to
be 3.17 (1 + ((1 + cv [2]) m - 1) x ICC) [27]. The initial
total sample size, ignoring clustering is 720 (total in both
arms) [28], therefore 2,282 accounting for the design
effect. Including a 10 percent withdrawal this equates to
46 practices.
Ethical considerations
As a cluster randomised trial, with practices as partici-
pants, the trial has specific ethical considerations. We
seek informed consent to participate from the practices,
with a practice ‘guardian’ consenting to trial entry
[21,22] on the basis that the guardian will act for the
good of the cluster; benefits and harms of entry to the
trial will not exceed non-entry and the intervention will
not be too onerous or contentious for cluster members
[22]. Interview participants will give individual informed
consent. We shall use data from the primary care med-
ical records; however we will only receive anonymised
pro forma data or data aggregated to a practice level. Fi-
nally, we shall employ a data monitoring committee to
monitor study progress for safety, notably the secondary
outcomes (inappropriate prescribing, stoke, TIA, and
haemorrhages).
The study protocol and associated material have re-
ceived a full favourable opinion from the NRES Commit-
tee South Central - Berkshire (REC number 13/SC/
0026); and national NHS research and development ap-
proval. We have registered the trial on the International
Standard Randomised Controlled Trial Number Register
(ISRCTN55722437) and the UK Clinical Research Net-
work portfolio. We have developed the full study proto-
col in line with SPIRIT guidelines (full protocol available
on request) [29], and will conduct and report the trial in
line with the CONSORT extension to cluster rando-
mised trials [24].
Discussion
AURAS-AF investigates whether a reminder interven-
tion, using electronic primary care records, can safely in-
crease anticoagulant uptake in a high stroke risk group
with AF. This has been recognised as an important area
for stroke prevention, and one that has lagged behind
improvements in other areas of stroke care [8,30]. A
number of barriers to anticoagulation have been pro-
posed, however, their precise importance remainsunclear [12]. Given the relative complexity of stoke risk
scoring tools, and recently changing guidelines for
anticoagulant eligibility, clinician uncertainty may play a
role [14]. The use of automated tools that harness elec-
tronic data in primary care may clarify which patients
with AF are eligible for OAC and flag this risk during
routine care.
Electronic reminders are now commonplace in UK
primary care, but the evidence to support their use is
disproportionately low. Few have been assessed in
randomised trials [31,32], and questions remain as to
whether the quality of the underlying data is suffi-
cient to risk assess patients for serious outcomes
[8,33]. The evidence behind consultation based re-
minders is especially important when considering
their potential for harm, or more specifically their
disruptiveness and/or irrelevance to the clinical prob-
lem at hand. It has been proposed that such re-
minders may reduce patient autonomy; lengthen
consultations excessively; and lead to clinician reli-
ance [16-18]. Finally, for AF, the prompts could rush
clinicians into unsafe prescribing. There is little sub-
stantive evidence to support, or dispel, these con-
cerns. Our process evaluation of the AURAS-AF
intervention will provide valuable data, especially
qualitative, on the safety and suitability of electronic
reminders in this area of care. We anticipate that
prescribing may in fact be safer through use of the
tool - with the most recent national eligibility criteria
applied systematically to patient data - but this as-
sumption requires confirmation though this research
[19]. Reports of inappropriate prescribing in the study
will therefore be important outcomes.
Finally, the AURAS-AF trial will test a relatively
new approach to conducting primary care research.
Recent studies have utilised primary care databases to
facilitate randomised controlled trials [32,34]. We will
use the capabilities of a web-based clinical system
both to deploy a primary care intervention and to
collect outcome data. There has been a very recent
move to generate data for cross-sectional analyses
through the anonymous extraction from medical re-
cords via this method [35,36]. Use of this extraction
process for a randomised trial may substantially re-
duce costs of data collection and provides a novel
platform for the study of interventions and processes
of care in a range of clinical areas.Trial status
The intervention tool has been developed and the pilot
study began on 21 June 2013. Recruitment for the main
phase began on 1 July 2013, with an anticipated start
date of 1 December 2013.
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